Obtenga las últimas noticias sobre las acciones de Hepion Pharmaceuticals con actualizaciones sobre las tendencias del mercado, las finanzas y el análisis de Benzinga. Manténgase informado sobre el rendimiento de HEPA

Últimas noticias sobre

Hepion Pharmaceuticals

Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan-cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.

Stock Movers

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ADTX

ANAB

ANIK

ANNA

AREB

ASBP

CDLX

ELME

FAMI

HEPA

INTC

NOVA

PATH

SGBX

SNES

STGW

YOSH

Intel designa un nuevo CEO y sus acciones suben con fuerza en el premercado. Descubre qué otros valores destacan hoy.

Las acciones de Intel suben más del 10%; 20 acciones que se están moviendo en el premercado

ACTU

ALVO

BACK

CSBR

EVGR

GLRE

JDZG

JYNT

LUNG

PRTA

SRRK

UNTY

VREX

YIBO

ZKIN

IMAC Holdings sube más del 108% tras anunciar Ignite Proteomics. Conoce las acciones más destacadas en la negociación previa.

Acciones de IMAC Holdings se disparan un 108%; 20 acciones en movimiento en el premercado de EE.UU.

HEPION PHARMS INC by Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals Inc

Press Releases

Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Effectiveness of Registration Statement Related to Proposed Merger

Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B

Health Care

General

Pharma Two B Announces Poster Presentation on P2B001 at the Annual Meeting of the Parkinson's Disease Study Group

Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd.

Hepion Pharmaceuticals Announces $9.0 Million Public Offering

Hepion Pharmaceuticals Announces Reverse Stock Split

Hepion Pharmaceuticals Executes Binding Letter of Intent with New Day Diagnostics to Commercialize Diagnostic Tests for Celiac Disease, Respiratory Multiplex, H. Pylori and HCC

Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq

Hepion Pharmaceuticals Announces Dr. Kaouthar Lbiati as Interim Chief Executive Officer

Hepion Pharmaceuticals Successfully Completes Application to the OTCQB

Comments

Hepion Pharmaceuticals Noticias bursátiles

Noticias

Últimas noticias sobre

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL